Skip to main content
Clinical Trials/CTRI/2018/03/012266
CTRI/2018/03/012266Recruiting未知

Genzyme Rare disease registries (MPS I Disease Registry Protocol).

Sanofi Synthelabo India Private Limited0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • 1. All age group from new born to old age allowed
  • 2. All patients with a confirmed diagnosis of MPS I disease who are willing and able to provide written informed consent and any additional authorization documents required by local law to send health information to the Registry are eligible for inclusion, regardless of whether they are receiving disease therapy including ERT (such as laronidase) and irrespective of the commercial product with which they are being treated.
  • 3. A confirmed diagnosis of MPS I consists of documented biochemical evidence of a deficiency in α-Liduronidase enzyme activity or mutation(s) in the gene coding for α-L-iduronidase

Exclusion Criteria

  • No Exclusion Criteria

Investigators

Sponsor
Sanofi Synthelabo India Private Limited

Similar Trials

Disease Registry for patients with MPS I... | Clinical Trial